Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | dopamine receptor D3 | Starlite/ChEMBL | References |
Homo sapiens | dopamine receptor D2 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | hypothetical protein | dopamine receptor D3 | 400 aa | 392 aa | 19.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | AGC family protein kinase | 0.0663 | 1 | 0.5 |
Trypanosoma brucei | eukaryotic translation initiation factor 2-alpha kinase 2 | 0.0663 | 1 | 0.5 |
Plasmodium vivax | serine/threonine protein kinase, putative | 0.0663 | 1 | 0.5 |
Trypanosoma cruzi | Eukaryotic translation initiation factor 2-alpha kinase 2 | 0.0663 | 1 | 1 |
Trichomonas vaginalis | STE family protein kinase | 0.0663 | 1 | 0.5 |
Trypanosoma cruzi | Eukaryotic translation initiation factor 2-alpha kinase 2 | 0.0663 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (binding) | Agonist activity at human D2LR expressed in CHO-K1 cells assessed as stimulation of basal activity by beta-galactosidase based beta-arrestin recruitment assay | ChEMBL. | 25126833 | |
Activity (binding) | Agonist activity at D3R in human U2OS cells assessed as stimulation of basal activity by beta-galactosidase based beta-arrestin recruitment assay | ChEMBL. | 25126833 | |
IC50 (binding) | = 29 nM | Antagonist activity against D3R in human U2OS cells assessed as inhibition of (+)-PD128907-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay | ChEMBL. | 25126833 |
IC50 (binding) | = 281 nM | Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay | ChEMBL. | 25126833 |
Inhibition (binding) | Inverse agonist activity at D3R in human U2OS cells assessed as inhibition of basal activity by beta-galactosidase based beta-arrestin recruitment assay | ChEMBL. | 25126833 | |
Inhibition (binding) | Inverse agonist activity at human D2LR expressed in CHO-K1 cells assessed as inhibition of basal activity by beta-galactosidase based beta-arrestin recruitment assay | ChEMBL. | 25126833 | |
Ki (binding) | = 12 nM | Displacement of [125I]IABN from human D3R E90A mutant expressed in HEK293 cell membranes by gamma counting method | ChEMBL. | 25126833 |
Ki (binding) | = 12 nM | Displacement of [125I]IABN from human D3R E90Q mutant expressed in HEK293 cell membranes by gamma counting method | ChEMBL. | 25126833 |
Ki (binding) | = 16 nM | Displacement of [125I]IABN from wild type human D3R expressed in HEK293 cell membranes by gamma counting method | ChEMBL. | 25126833 |
Ki (binding) | = 24 nM | Displacement of [125I]IABN from human D3R S182I mutant expressed in HEK293 cell membranes by gamma counting method | ChEMBL. | 25126833 |
Ki (binding) | = 27 nM | Displacement of [125I]IABN from human D3R expressed in HEK293 cell membranes by gamma counting method | ChEMBL. | 25126833 |
Ki (binding) | = 44 nM | Displacement of [125I]IABN from chimeric human D3 receptor possessing extracellular loop II of D2 receptor expressed in HEK293 cell membranes by gamma counting method | ChEMBL. | 25126833 |
Ki (binding) | = 176 nM | Displacement of [125I]IABN from chimeric human D2 receptor possessing extracellular loop II of D3 receptor expressed in HEK293 cell membranes by gamma counting method | ChEMBL. | 25126833 |
Ki (binding) | = 245 nM | Displacement of [125I]IABN from wild type human D2R expressed in HEK293 cell membranes by gamma counting method | ChEMBL. | 25126833 |
Ki (binding) | = 298 nM | Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method | ChEMBL. | 25126833 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.